What was the market valuation of poultry vaccines in Japan in 2024?

The market valuation of poultry vaccines in Japan was $61.5 Million in 2024. Read More

What is the projected market valuation for poultry vaccines in Japan by 2035?

The projected market valuation for poultry vaccines in Japan is $120.0 Million by 2035. Read More

What is the expected CAGR for the Japan poultry vaccines market during the forecast period 2025 - 2035?

The expected CAGR for the Japan poultry vaccines market during the forecast period 2025 - 2035 is 6.26%. Read More

Which companies are considered key players in the Japan poultry vaccines market?

Key players in the Japan poultry vaccines market include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, and Ceva Santé Animale. Read More

What are the main types of poultry vaccines available in Japan and their market values?

The main types of poultry vaccines in Japan include Live Attenuated Vaccines ($20.0 - $40.0 Million), Inactivated Vaccines ($15.0 - $30.0 Million), Subunit Vaccines ($10.0 - $25.0 Million), and DNA Vaccines ($16.5 - $25.0 Million). Read More

How do the market values for different poultry species compare in Japan?

In Japan, the market values for poultry species are Broilers ($30.0 - $58.0 Million), Layers ($20.0 - $40.0 Million), Turkeys ($7.5 - $15.0 Million), and Others ($4.0 - $7.0 Million). Read More

What are the various administration routes for poultry vaccines in Japan and their respective market values?

The administration routes for poultry vaccines in Japan include Intramuscular ($20.0 - $40.0 Million), Subcutaneous ($15.0 - $30.0 Million), Oral ($16.5 - $30.0 Million), and Inhalation ($10.0 - $20.0 Million). Read More

Which diseases are targeted by poultry vaccines in Japan and what are their market values?

Poultry vaccines in Japan target diseases such as Newcastle Disease ($15.0 - $30.0 Million), Infectious Bursal Disease ($12.0 - $25.0 Million), Avian Influenza ($20.0 - $40.0 Million), and Marek's Disease ($14.5 - $25.0 Million). Read More

How does the growth of the Japan poultry vaccines market reflect on the overall industry trends?

The growth of the Japan poultry vaccines market, projected to reach $120.0 Million by 2035, reflects a robust demand for poultry health management and disease prevention. Read More

What factors may influence the future growth of the poultry vaccines market in Japan?

Factors influencing future growth may include advancements in vaccine technology, increasing poultry production, and heightened awareness of animal health. Read More

Japan Poultry Vaccines Market

Japan Poultry Vaccines Market Research Report: Size, Share, Trend Analysis By Types (Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, DNA Vaccines), By Species (Broilers, Layers, Turkeys, Others), By Administration Route (Intramuscular, Subcutaneous, Oral, Inhalation) and By Disease Targeted (Newcastle Disease, Infectious Bursal Disease, Avian Influenza, Marek's Disease) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.26%

2024 Market Size

$ 61.5 Million

2035 Market Size

$ 120 Million

Pharmaceutical ● Updated August 2026 Report ID: MRFR/Pharma/48778-HCR | Pages: 200 | Author: Vikita Thakur, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Type (USD Million)
  1. 4.1.1 Live Attenuated Vaccines
  2. 4.1.2 Inactivated Vaccines
  3. 4.1.3 Subunit Vaccines
  4. 4.1.4 DNA Vaccines
2. 4.2 Life Sciences, BY Species (USD Million)
  1. 4.2.1 Broilers
  2. 4.2.2 Layers
  3. 4.2.3 Turkeys
  4. 4.2.4 Others
3. 4.3 Life Sciences, BY Administration Route (USD Million)
  1. 4.3.1 Intramuscular
  2. 4.3.2 Subcutaneous
  3. 4.3.3 Oral
  4. 4.3.4 Inhalation
4. 4.4 Life Sciences, BY Disease Targeted (USD Million)
  1. 4.4.1 Newcastle Disease
  2. 4.4.2 Infectious Bursal Disease
  3. 4.4.3 Avian Influenza
  4. 4.4.4 Marek's Disease
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Zoetis (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck Animal Health (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Elanco Animal Health (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Ceva Santé Animale (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Heska Corporation (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Vetoquinol (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Phibro Animal Health (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 IDT Biologika (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 JAPAN MARKET ANALYSIS BY TYPE
3. 6.3 JAPAN MARKET ANALYSIS BY SPECIES
4. 6.4 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
5. 6.5 JAPAN MARKET ANALYSIS BY DISEASE TARGETED
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY SPECIES, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY SPECIES, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY DISEASE TARGETED, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY DISEASE TARGETED, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY SPECIES, 2025-2035 (USD Million)
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
  4. 7.2.4 BY DISEASE TARGETED, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Japan Poultry Vaccines Market Segmentation

Japan Poultry Vaccines Market By Type (USD Million, 2025-2035)

Live Attenuated Vaccines
Inactivated Vaccines
Subunit Vaccines
DNA Vaccines

Japan Poultry Vaccines Market By Species (USD Million, 2025-2035)

Broilers
Layers
Turkeys
Others

Japan Poultry Vaccines Market By Administration Route (USD Million, 2025-2035)

Intramuscular
Subcutaneous
Oral
Inhalation

Japan Poultry Vaccines Market By Disease Targeted (USD Million, 2025-2035)

Newcastle Disease
Infectious Bursal Disease
Avian Influenza
Marek's Disease

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”